BIONTECH SE (BNTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$103.76+0.86%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · BNTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
No current thesis-health read is available for this company.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -23.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is on a run of consecutive earnings misses and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
Why it matters: If revenue growth speeds up, it could signal a stronger market for BioNTech's products.
Supportive ifSector revenue growth rises back above 10% year over year.
Worry ifSector revenue growth stays below 9% year over year.
Why it matters: If revenue growth falls below its median, it signals a slowdown in the sector. This could impact investor confidence in BioNTech's growth potential.
Worry ifRevenue growth reported below the median growth rate for the healthcare sector.
Less concerning ifRevenue growth remains above the median growth rate for the healthcare sector.
Why it matters: Strong performance from peers may impact BioNTech's market position. It highlights the competitive landscape in the biotech sector.
Worry ifLilly or AbbVie may announce new drug approvals or revenue growth over 15%.
Less concerning ifLilly and AbbVie report disappointing results or slow growth below 5%.
Why it matters: If revenue growth speeds up, it could mean good news for BioNTech.
Supportive ifHealth care sector revenue growth accelerates back toward highs above 12%.
Worry ifSector revenue growth keeps slowing down and is now below 8%.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$116 on $10,000 · ±1.2% | How much price usually moves either way. |
| Bad day | $386 loss on $10,000 · 3.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,971 loss on $10,000 · 29.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A drop below the median signals a slowdown in the healthcare sector's growth phase.
Worry ifQ2 revenue growth reported below the median growth rate for the sector.
Less concerning ifQ2 revenue growth remains above the median growth rate for the sector.
Why it matters: If revenue growth picks up, it may signal a positive trend for the sector. This could improve investor confidence in BioNTech's future.
Supportive ifBioNTech reports revenue growth above 10% in its next earnings report.
Worry ifRevenue growth is below 9%. This shows it is still slowing down.